Todd DeVries

1.7k total citations
58 papers, 1.3k citations indexed

About

Todd DeVries is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Todd DeVries has authored 58 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 19 papers in Immunology. Recurrent topics in Todd DeVries's work include Cancer Immunotherapy and Biomarkers (26 papers), Prostate Cancer Treatment and Research (20 papers) and CAR-T cell therapy research (15 papers). Todd DeVries is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Prostate Cancer Treatment and Research (20 papers) and CAR-T cell therapy research (15 papers). Todd DeVries collaborates with scholars based in United States, Australia and South Korea. Todd DeVries's co-authors include Michael R. Lovy, Daniel Burge, Shelly Kafka, Joel M. Kremer, Edward Keystone, Michael Schiff, Nadeem A. Sheikh, Diana F. Hausman, Eric J. Small and Thomas A. Gardner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Todd DeVries

55 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Todd DeVries United States	16	666	590	264	257	232	58	1.3k
Amit Jain United States	16	776 1.2×	661 1.1×	500 1.9×	427 1.7×	79 0.3×	60	1.7k
Mohammad Tabrizi United States	14	354 0.5×	389 0.7×	202 0.8×	554 2.2×	45 0.2×	26	1.3k
Joseph G. Pressey United States	23	512 0.8×	216 0.4×	478 1.8×	550 2.1×	161 0.7×	72	1.5k
Amitkumar Mehta United States	20	834 1.3×	349 0.6×	103 0.4×	240 0.9×	35 0.2×	114	1.3k
John A. Zic United States	20	281 0.4×	437 0.7×	160 0.6×	116 0.5×	74 0.3×	46	1.5k
Michiel Kroesen Netherlands	12	464 0.7×	559 0.9×	120 0.5×	350 1.4×	51 0.2×	21	1.2k
Italia Grenga United States	20	1.1k 1.7×	617 1.0×	337 1.3×	326 1.3×	66 0.3×	43	1.6k
Fionnuala O’Connell Ireland	14	406 0.6×	133 0.2×	255 1.0×	468 1.8×	33 0.1×	22	1.2k
Tomoya Kishimoto Japan	10	525 0.8×	381 0.6×	95 0.4×	758 2.9×	39 0.2×	34	1.3k
Tim Luetkens United States	23	658 1.0×	718 1.2×	81 0.3×	469 1.8×	20 0.1×	57	1.4k

Countries citing papers authored by Todd DeVries

Since Specialization

Citations

This map shows the geographic impact of Todd DeVries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd DeVries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd DeVries more than expected).

Fields of papers citing papers by Todd DeVries

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd DeVries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd DeVries. The network helps show where Todd DeVries may publish in the future.

Co-authorship network of co-authors of Todd DeVries

This figure shows the co-authorship network connecting the top 25 collaborators of Todd DeVries. A scholar is included among the top collaborators of Todd DeVries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd DeVries. Todd DeVries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DeVries, Todd, et al.. (2024). A practical guide to the appropriate analysis of eGFR data over time: A simulation study. Pharmaceutical Statistics. 23(5). 742–762.

Kim, Sung‐Hoon, Richard Lafayette, Eugenie Pedagogos, et al.. (2023). WCN23-1117 ATRASENTAN IN PATIENTS WITH PROTEINURIC GLOMERULAR DISEASES – THE AFFINITY STUDY. Kidney International Reports. 8(9). 1902–1902.

Packham, David, Anjay Rastogi, Michelle N. Rheault, et al.. (2023). WCN23-1126 ATRASENTAN FOR THE TREATMENT OF IGA NEPHROPATHY: INTERIM RESULTS OF THE AFFINITY STUDY. Kidney International Reports. 8(9). 1902–1902. 9 indexed citations

Larson, Ryan, Todd DeVries, Yue Jiang, et al.. (2018). Abstract 960: Defined cell composition and precise control over JCAR017 dose enables identification of relationships between chimeric antigen receptor T cell product attributes, pharmacokinetics, and clinical endpoints in NHL. Cancer Research. 78(13_Supplement). 960–960. 1 indexed citations

Heipel, Mark, Jeffrey A. Smith, Mandana Karimi, et al.. (2017). Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017. Blood. 130. 2835–2835. 1 indexed citations

Siddiqi, Tanya, Jeremy S. Abramson, D. Li, et al.. (2017). Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017. Blood. 130. 193–193. 14 indexed citations

Sheikh, Nadeem A., Jason Cham, Li Zhang, et al.. (2016). Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects. Cancer Research. 76(13). 3711–3718. 50 indexed citations

Antonarakis, Emmanuel S., Adam S. Kibel, Evan Y. Yu, et al.. (2016). Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clinical Cancer Research. 23(10). 2451–2459. 60 indexed citations

Georgiev, Pencho, David Belada, Shaker R. Dakhil, et al.. (2016). Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma. Annals of Oncology. 27. vi324–vi324.

10.

GuhaThakurta, Debraj, Nadeem A. Sheikh, Li-Qun Fan, et al.. (2015). Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clinical Cancer Research. 21(16). 3619–3630. 101 indexed citations

11.

Small, Eric J., Raymond S. Lance, Thomas A. Gardner, et al.. (2015). A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 21(17). 3862–3869. 61 indexed citations

12.

George, Daniel J., Chadi Nabhan, Todd DeVries, James B. Whitmore, & Leonard G. Gomella. (2015). Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy. Cancer Immunology Research. 3(9). 1063–1069. 19 indexed citations

13.

McNeel, Douglas G., Thomas A. Gardner, Celestia S. Higano, et al.. (2014). A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. Cancer Immunology Research. 2(10). 988–999. 44 indexed citations

14.

Bajorin, Dean F., Leonard G. Gomella, Padmanee Sharma, et al.. (2014). Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.. Journal of Clinical Oncology. 32(15_suppl). 4541–4541. 5 indexed citations

15.

Quinn, David I., Daniel P. Petrylak, Christopher Pieczonka, et al.. (2014). A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 32(15_suppl). e16071–e16071. 8 indexed citations

16.

Bhatia, Shailender, Brendan D. Curti, Michael A. Gordon, et al.. (2007). Recombinant IL-21 in combination with sorafenib: Preliminary results from a phase I/II study in patients with metastatic renal cell cancer. Molecular Cancer Therapeutics. 6. 2 indexed citations

17.

Nestorov, Ivan, Ralph Zitnik, Todd DeVries, et al.. (2006). Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. British Journal of Clinical Pharmacology. 62(4). 435–445. 40 indexed citations

18.

Ansell, Stephen M., Thomas E. Witzig, Anne J. Novak, et al.. (2006). Phase 1 Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma.. Blood. 108(11). 2722–2722. 1 indexed citations

19.

Keystone, Edward, Michael Schiff, Joel M. Kremer, et al.. (2004). Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumatism. 50(2). 353–363. 227 indexed citations

20.

Landin, Ronald J., David J. DeBrota, Todd DeVries, William Z. Potter, & Mark A. Demitrack. (2000). The Impact of Restrictive Entry Criterion During the Placebo Lead‐in Period. Biometrics. 56(1). 271–278. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact